期刊文献+

骨髓增生异常综合征的DNA去甲基化治疗策略 被引量:1

DNA demethylation treatment strategies of myelodysplastic syndrome
原文传递
导出
摘要 骨髓增生异常综合征(myelodysplastic syndromes,MDS)是一组起源于造血干/祖细胞异质性明显的恶性克隆性疾病,其发病机制涉及遗传学和表观遗传学等多个层面。当前去甲基化治疗已经成为MDS的一线治疗方案之一,美国FDA陆续批准5-阿扎胞苷和地西他滨应用于MDS所有亚型的治疗。随着近年对MDS表观遗传发病机制和去甲基化药物作用的进一步认识以及临床用药经验的积累,去甲基化治疗的策略正在进一步规范化及个体化。
作者 李晓
出处 《临床血液学杂志》 CAS 2014年第1期1-4,共4页 Journal of Clinical Hematology
关键词 骨髓增生异常综合征 DNA去甲基化治疗 myelodysplastic syndrome DNA demethylation treatment
  • 相关文献

参考文献32

  • 1LI K K,LUO L F,SHEN Y,et al. DNA methyltrans ferases in hematologic malignancies[J]. Semin Hema tol,2013,50:48--60.
  • 2ISSA J P. The myelodysplastic syndrome as a proto- typical epigenetic disease[J]. Blood,2013,121:3811-- 3817.
  • 3SIGALOTTI L, FRATTA E, CORAL S, et al. Intra- tumor heterogeneity of cancer/testis antigens expres- sion in human cutaneous melanoma is methylation- regulated and functionally reverted by 5-aza-2-deoxy- cytidine[J]. Cancer Res, 2004,64 : 9167 -- 9171.
  • 4HU Y, CUI Q, GU Y, et al. Decitabine facilitates the generation and immunosuppressive function of regula- tory )'c3T cells derived from human peripheral blood mononuclear cells [J]. Leukemia, 2013, 27:1580 -- 1585.
  • 5SAUNTHARARAJAH Y, TRIOZZI P, RINI B, et al. p53 Independent, normal stem cell sparing epige- netic differentiation therapy for myeloid and other malignancies[J]. Semin Oncol, 2012,39 : 97-- 108.
  • 6VALDEZ B C,LI Y, MURRAY D,et al. 5-Aza2"-de- oxycytidine sensitizes busulfan-resistant myeloid leu- kemia cells by regulating expression of genes involved in cell cycle checkpoint and apoptosis[J]. Leuk Res, 2010,34:364--372.
  • 7KANTARJIAN H, ISSA J P,ROSENFELD C S, et al. Decitabine improves patient outcomes in myelodys- plastic syndromes: results of a phase III randomized study[J]. Cancer, 2006,106 : 1794-- 1803.
  • 8WIJERMANS P,LUBBERT M,VERHOEF G,et al. Low-dose 5-aza-2"-deoxycytidine, a DNA hypomethyl- ating agent, for the treatment of high-risk myelodys- plastic syndrome:a multicenter phase II study in eld- erly patients[J]. J Clin Oncol, 2000,18 : 956-- 962.
  • 9KANTARJIAN H, OKI Y, GARCIA-MANERO G, et al. Results of a randomized study of 3 schedules of low-dose decitahine in higher-risk myelodysplastic syndrome and chronic myelomonoeytic leukemia[J]. Blood, 2007,109 : 52-- 57.
  • 10LI X, CHANG C, HE Q, et al. Cytogenetic response based on revised IPSS cytogenetic risk stratification and minimal residual disease monitoring by FISH in MDS patients treated with low-dose decitabine[J]. Leuk Res,2013,37 : 1516-- 1521.

同被引文献14

引证文献1

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部